AKUMS · NSE
Akums Drugs and Pharmaceuticals Limited
₹783.7
+2.22% (+₹17)
Prev. close
₹766.7
Volume
3,30,477
Delivery %
61.7%
As of
18 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About Akums Drugs and Pharmaceuticals Limited
Akums Drugs and Pharmaceuticals Limited manufactures and sells pharmaceutical products and active pharmaceutical ingredients India and internationally. The company provides drugs, ayurvedic, nutraceuticals, food and dietary supplements, derma and cosmetics, healthcare and hospital products, over-the-counter (OTC) products, active pharmaceutical ingredients, excipients, and compounds. It also offers branded formulations on various dosage forms, including tablets, hard and soft gelatin capsules, liquid orals, sachets, vials, ampoules, form-fill-seal products, topical preparations, eye drops, dry powder injections, and gummies for therapeutic areas, such as antiinfectives, pain management, gastroenterology, orthopaedics, cardio-diabetic care, critical care, respiratory, and gynaecology. In addition, the company operates as pharmaceutical contract development and manufacturing company. Akums Drugs and Pharmaceuticals Limited was incorporated in 2004 and is based in Delhi, India.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Sanjeev Jain
Headquarters
Delhi
Employees
7,337
Website
akums.inExchange
View on NSE ↗Key stats
Market cap
₹11,998.61 Cr
P/E ratio (TTM)
41.2
Dividend yield
0.13%
EPS (TTM)
₹19.01
Beta (1Y · daily vs NIFTY 50)
0.97
Shares float
3.46 Cr
EPS · quarter ended Jun 2026
₹6.53
Financial Performance
01 · Financials
FY21 growth needs FY20 filings, which the data source doesn't provide. EBITDA is omitted from this chart: coverage begins inside the plotted window, and every plotted period must carry a complete point set — the P&L table below has the available figures.
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | — | ₹3,474.76 Cr | ₹4,019.68 Cr | ₹4,071.09 Cr | ₹4,359.02 Cr | |
| EBITDA | — | — | ₹309.08 Cr | ₹130.61 Cr | ₹529.11 Cr | ₹630.73 Cr |
| ₹123.00 Cr | ₹-253.00 Cr | ₹94.86 Cr | ₹-4.04 Cr | ₹338.18 Cr | ₹255.19 Cr | |
| Diluted EPS | — | — | ₹6.03 | ₹-0.28 | ₹22.6 | ₹16.67 |
Revenue, Total expenses (as filed), Employee benefit expense, Other expenses, EBITDA, Tax provision, Other income, Diluted EPS have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹2,152.00 Cr | ₹3,050.00 Cr | ₹3,241.00 Cr | ₹3,504.00 Cr | ₹4,095.00 Cr | ₹5,429.00 Cr | |
| — | — | ₹619.09 Cr | ₹565.23 Cr | ₹88.21 Cr | ₹191.74 Cr | |
| Stockholders' equity | ₹885.00 Cr | ₹622.00 Cr | ₹718.00 Cr | ₹710.00 Cr | ₹3,047.00 Cr | ₹3,314.00 Cr |
Current assets, Inventory, Trade receivables, Cash & equivalents, Non-current assets, CWIP, Others, Total debt, Long-term debt, Current (short-term) debt have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹131.00 Cr | ₹32.00 Cr | ₹177.00 Cr | ₹498.00 Cr | ₹465.00 Cr | ₹1,181.00 Cr | |
| Investing cash flow | — | — | ₹-304.70 Cr | ₹-330.42 Cr | ₹-547.84 Cr | ₹-930.27 Cr |
| ₹-91.00 Cr | ₹236.00 Cr | ₹125.00 Cr | ₹-108.00 Cr | ₹73.00 Cr | ₹34.00 Cr | |
| Capital expenditure | ₹-83.00 Cr | ₹-258.00 Cr | ₹-329.00 Cr | ₹-311.00 Cr | ₹-272.00 Cr | ₹-231.00 Cr |
| End cash position | — | — | ₹51.61 Cr | ₹111.05 Cr | ₹101.19 Cr | ₹386.01 Cr |
Change in working capital, Investing cash flow, Dividends paid, End cash position have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Aug 24–Jun 26(9Q) |
|---|---|
| Promoter | 75.26% |
| Public | 22.01% |
| Employee trusts | 2.73% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| Akums Drugs and Pharmaceuticals Limited | ₹11,738.34 Cr | ₹783.7 | 40.2 | 3.54 | 7.7% | 0.06 | +4.4% | +65.0% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
IPO documents
Annual reports
Concall transcripts
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Index membership
10 indices
NSE weights are a free-float market-cap-share estimate, not NSE’s own published (and sometimes capped) index weight. BSE weights are BSE’s own published index weight, not an estimate. Indices without weight data are listed without one, in alphabetical order after the weighted ones.
Akums Drugs and Pharmaceuticals share price: Good Buy After Q1 FY27 Results?
Univest · 12 days ago
Akums Drugs: Citi hikes target to Rs 860, sees 15% upside on CDMO strength
Citi maintained a Buy rating on Akums Drugs and Pharmaceuticals, raising its target price to Rs 860 from Rs 610, implying a 15% upside. This revision reflects improving earnings quality driven by the company's CDMO strength and a more positive outlook on API pricing. Citi also increased its FY27E and FY28E EPS estimates.